Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis

International Journal of Impotence Research volume 18, pages 223–228 (2006)Cite this article

Abstract

Male hypogonadism has a multifactorial etiology that includes genetic conditions, anatomic abnormalities, infection, tumor, and injury. Defects in the hypothalamic-pituitary-gonadal axis may also result from type II diabetes mellitus and treatment with a range of medications. Circulating testosterone levels have been associated with sexual function, cognitive function, and body composition. Apart from reduced levels of testosterone, clinical hallmarks of hypogonadism include absence or regression of secondary sex characteristics, reduced fertility (oligospermia, azoospermia), anemia, muscle wasting, reduced bone mass (and bone mineral density), and/or abdominal adiposity. Some patients, particularly those with partial androgen deficiency of the aging male, also experience sexual dysfunction, reduced sense of vitality, depressed mood, increased irritability, difficulty concentrating, and/or hot flushes in certain cases of acute onset. As many patients with male hypogonadism—like patients with erectile dysfunction—do not seek medical attention, it is important for clinicians to be acquainted with the signs and symptoms of hypogonadism, and to conduct appropriate laboratory testing and other assessments to determine the causes and inform the treatment of this condition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Rhoden EL, Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.

    Article  CAS  PubMed  Google Scholar 

  2. American Association of Clinical Endocrinologists. Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients: 2002 update. Endocr Pract 2002; 8: 440–456.

  3. Hameed A, Brothwood T, Bouloux P . Delivery of testosterone replacement therapy. Curr Opin Invest Drugs 2003; 4: 1213–1219.

    CAS  Google Scholar 

  4. Rehman J, Melman A . Pathophysiology of erectile dysfunction. In: Lue TF, Goldstein M, Vaughan Jr ED, Perlmutter AP, (eds.), Impotence and Infertility. Atlas of Clinical Urology vol. 1, Philadelphia, PA: Current Medicine, Inc., 1999, pp. 1.1–1.16.

    Google Scholar 

  5. Morley JE, Melmed S . Gonadal dysfunction in systemic disorders. Metabolism 1979; 28: 1051–1073.

    Article  CAS  PubMed  Google Scholar 

  6. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N et al. Testosterone dose–response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172–E1181.

    Article  CAS  PubMed  Google Scholar 

  7. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 2004; 89: 718–726.

    Article  CAS  PubMed  Google Scholar 

  8. Kelleher S, Conway AJ, Handelsman DJ . Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813–3817.

    Article  CAS  PubMed  Google Scholar 

  9. Vermeulen A . Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab 2001; 86: 2380–2390.

    CAS  PubMed  Google Scholar 

  10. King BE, Packard MG, Alexander GM . Affective properties of intra-medial preoptic area injections of testosterone in male rats. Neurosci Lett 1999; 269: 149–152.

    Article  CAS  PubMed  Google Scholar 

  11. Mills TM, Reilly CM, Lewis RW . Androgens and penile erection: a review. J Androl 1996; 17: 633–638.

    CAS  PubMed  Google Scholar 

  12. Baba K, Yajima M, Carrier S, Morgan DM, Nunes L, Lue TF et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int 2000; 85: 953–958.

    Article  CAS  PubMed  Google Scholar 

  13. Reilly CM, Stopper VS, Mills TM . Androgens modulate the α-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997; 18: 26–31.

    CAS  PubMed  Google Scholar 

  14. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709–5717.

    Article  CAS  PubMed  Google Scholar 

  15. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003; 24: 381–387.

    Article  PubMed  Google Scholar 

  16. Carani C, Scuteri A, Marrama P, Bancroft J . The effects of testosterone administration and visual erotic stimuli on nocturnal penile tumescence in normal men. Horm Behav 1990; 24: 435–441.

    Article  CAS  PubMed  Google Scholar 

  17. Lugg JA, Rajfer J, Gonzalez-Cadavid NF . Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995; 136: 1495–1501.

    Article  CAS  PubMed  Google Scholar 

  18. Davidson JM, Kwan M, Greenleaf WJ . Hormonal replacement and sexuality in men. Clin Endocrinol Metab 1982; 11: 599–623.

    Article  CAS  PubMed  Google Scholar 

  19. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U et al. Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction. Urology 2001; 58: 435–440.

    Article  CAS  PubMed  Google Scholar 

  20. Hooven CK, Chabris CF, Ellison PT, Kosslyn SM . The relationship of male testosterone to components of mental rotation. Neuropsychologia 2004; 42: 782–790.

    Article  PubMed  Google Scholar 

  21. Christiansen K, Knussmann R . Sex hormones and cognitive functioning in men. Neuropsychobiology 1987; 18: 27–36.

    Article  CAS  PubMed  Google Scholar 

  22. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B et al. Androgen–behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav 1998; 33: 85–94.

    Article  CAS  PubMed  Google Scholar 

  23. Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C . Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667.

    Article  CAS  PubMed  Google Scholar 

  24. Janowsky JS, Oviatt SK, Orwoll ES . Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325–332.

    Article  CAS  PubMed  Google Scholar 

  25. Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE et al. Androgens modulate β-amyloid levels in male rat brain. J Neurochem 2003; 87: 1052–1055.

    Article  CAS  PubMed  Google Scholar 

  26. Ramsden M, Shin TM, Pike CJ . Androgens modulate neuronal vulnerability to kainate lesion. Neuroscience 2003; 122: 573–578.

    Article  CAS  PubMed  Google Scholar 

  27. Ready RE, Friedman J, Grace J, Fernandez H . Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry 2004; 75: 1323–1326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S . Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004; 59: 75–78.

    Article  PubMed  Google Scholar 

  29. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D . Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573–577.

    Article  CAS  PubMed  Google Scholar 

  30. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24: 379–385.

    Article  CAS  PubMed  Google Scholar 

  31. Seidman SN, Spatz E, Rizzo C, Roose SP . Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 2001; 62: 406–412.

    Article  CAS  PubMed  Google Scholar 

  32. Pope Jr HG, Cohane GH, Kanayama G, Siegel AJ, Hudson JI . Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 105–111.

    Article  PubMed  Google Scholar 

  33. Carnahan RM, Perry PJ . Depression in aging men: the role of testosterone. Drugs Aging 2004; 21: 361–376.

    Article  CAS  PubMed  Google Scholar 

  34. Morley JE, Perry III HM, Kaiser FE, Kraenzle D, Jensen J, Houston K et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–152.

    Article  CAS  PubMed  Google Scholar 

  35. Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993; 59: 1118–1123.

    Article  CAS  PubMed  Google Scholar 

  36. Valimaki VV, Alfthan H, Ivaska KK, Loyttyniemi E, Pettersson K, Stenman UH et al. Serum estradiol, testosterone, and sex hormone-binding globulin as regulators of peak bone mass and bone turnover rate in young Finnish men. J Clin Endocrinol Metab 2004; 89: 3785–3789.

    Article  PubMed  Google Scholar 

  37. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA . IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol (Oxford) 2004; 60: 491–499.

    Article  CAS  Google Scholar 

  38. Abbasi AA, Drinka PJ, Mattson DE, Rudman D . Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Am Geriatr Soc 1993; 41: 975–982.

    Article  CAS  PubMed  Google Scholar 

  39. Herbst KL, Bhasin S . Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7: 271–277.

    Article  CAS  PubMed  Google Scholar 

  40. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW . Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276–3282.

    CAS  PubMed  Google Scholar 

  41. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ . Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123–136.

    Article  CAS  PubMed  Google Scholar 

  42. Verhaar HJJ, Samson MM, Aleman A, de Vries WR, de Vreede PL . The relationship between indices of muscle function and circulating anabolic hormones in healthy men. Aging Male 2000; 3: 75–80.

    Article  Google Scholar 

  43. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson K-E, Althof S et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6–23.

    Article  PubMed  Google Scholar 

  44. Bremner WJ, Vitiello MV, Prinz PN . Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278–1281.

    Article  CAS  PubMed  Google Scholar 

  45. Snyder PJ . Hypogonadism in elderly men: what to do until the evidence comes. N Engl J Med 2004; 350: 440–442.

    Article  CAS  PubMed  Google Scholar 

  46. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD . Use, misuse and abuse of androgens: The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000; 172: 220–224.

    CAS  PubMed  Google Scholar 

  47. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB . Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol 2005; 62: 64–73.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Case Western Reserve University, Cleveland, OH, USA

    A Seftel

Authors
  1. A Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Seftel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seftel, A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res 18, 223–228 (2006). https://doi.org/10.1038/sj.ijir.3901365

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901365

Keywords

This article is cited by

Search

Advanced search

Quick links